Clinical trial

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

NCT03250832

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention TSR-033 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dostarlimab Normalized identity: dostarlimabView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention mFOLFOX6 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention FOLFIRI Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Bevacizumab Normalized identity: bevacizumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-08-08

PhasePHASE1

Conditions

Neoplasmsunresolved

Interventions

TSR-033DRUG

DostarlimabDRUG · verified · RxNorm: dostarlimab

mFOLFOX6DRUG

FOLFIRIDRUG

BevacizumabDRUG · verified · RxNorm: bevacizumab

Sponsors & collaborators

Tesaro, Inc.lead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

HoustonTexas, United States1 BostonMassachusetts, United States1 Los AngelesCalifornia, United States1 San AntonioTexas, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1 TampaFlorida, United States1 Oklahoma CityOklahoma, United States1 GreenvilleSouth Carolina, United States1 VillejuifFrance1 SarasotaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03250832 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.